Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/25476
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.date.accessioned | 2022-03-31T07:15:38Z | - |
dc.date.available | 2022-03-31T07:15:38Z | - |
dc.date.issued | 2008-07-28 | - |
dc.identifier.citation | Cansev, M. vd. (2008). "Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: Involvement of the peripheral autonomic nervous system". European Journal of Pharmacology, 589(1-3), 315-322. | en_US |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.uri | https://doi.org/10.1016/j.ejphar.2008.05.017 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S001429990800561X | - |
dc.identifier.uri | http://hdl.handle.net/11452/25476 | - |
dc.description.abstract | The present study was designed to test the effects of choline, cytidine-5'-diphosphocholine (CDP-choline) and phosphocholine on plasma glucagon concentrations in rats. Intraperitoneal (i.p.) injection of 200-600 mu mol/kg of choline, CDP-choline or phosphocholine produced a dose-dependent increase in plasma glucagon and choline concentrations. Pretreatment with hexamethonium (15 mg/kg: i.p.), a peripherally-acting ganglionic nicotinic acetylcholine receptor antagonist, entirely blocked the increases in plasma glucagon by 600 mu mol/kg of choline, CDP-choline or phosphocholine. The increases in plasma glucagon by these choline compounds was reduced significantly (P<0.01) by about 25% by pretreatment with atropine methylnitrate (2 mg/kg), a peripherally-acting muscarinic acetylcholine receptor antagonist. Blockade of central acetylcholine receptors did not alter the increase in plasma glucagon induced by i.p. choline (600 mu mol/kg). While alpha(2)-adrenoceptor blockade or bilateral adrenalectomy attenuated the increase in plasma glucagon evoked by choline compounds, blockade of alpha(1)- or beta-adrenoceptors or chemical sympathectomy failed to alter this increase. Intracerebroventricular (i.c.v.) choline (1.5 mu mol) administration also increased plasma glucagon; the effect was blocked by central pretreatment with a neuronal type nicotinic acetylcholine receptor antagonist, mecamylamine (50 mu g; i.c.v.) or the neuronal choline uptake inhibitor, hemicholinium-3 (20 mu g; i.c.v.). These data show that choline, CDP-choline or phosphocholine increases plasma glucagon concentrations by increasing peripheral nicotinic and muscarinic cholinergic neurotransmissions. Central choline also increases plasma glucagon by augmenting central nicotinic cholinergic neurotransmission by acting presynaptically. Stimulation of adrenal medullary catecholamine release and subsequent activation of alpha(2)-adrenoceptors are mainly involved in the increase in plasma glucagon induced by choline, CDP-choline or phosphocholine. | en_US |
dc.description.sponsorship | TUBA | tr_TR |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Adrenoceptor | en_US |
dc.subject | Catecholamine | en_US |
dc.subject | CDP-choline | en_US |
dc.subject | Choline | en_US |
dc.subject | Glucagon | en_US |
dc.subject | Phosphocholine | en_US |
dc.subject | Nicotinic acetylcholine-receptors | en_US |
dc.subject | Sympathoadrenal system | en_US |
dc.subject | Tyrosine-hydroxylase | en_US |
dc.subject | Blood-pressure | en_US |
dc.subject | Serum-insulin | en_US |
dc.subject | Secretion | en_US |
dc.subject | Activation | en_US |
dc.subject | Hyperglycemia | en_US |
dc.subject | Metabolites | en_US |
dc.subject | Release | en_US |
dc.subject.mesh | Adrenal medulla | en_US |
dc.subject.mesh | Adrenalectomy | en_US |
dc.subject.mesh | Adrenergic alpha-antagonists | en_US |
dc.subject.mesh | Adrenergic beta-antagonists | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Autonomic nervous system | en_US |
dc.subject.mesh | Brain | en_US |
dc.subject.mesh | Choline | en_US |
dc.subject.mesh | Cytidine diphosphate choline | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Glucagon | en_US |
dc.subject.mesh | Injections, intraperitoneal | en_US |
dc.subject.mesh | Injections, intraventricular | en_US |
dc.subject.mesh | Muscarinic antagonists | en_US |
dc.subject.mesh | Neurotransmitter uptake inhibitors | en_US |
dc.subject.mesh | Muscarinic antagonists | en_US |
dc.subject.mesh | Nicotinic antagonists | en_US |
dc.subject.mesh | Phosphorylcholine | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, sprague-dawley | en_US |
dc.subject.mesh | Sympathectomy, chemical | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Up-regulation | en_US |
dc.subject.mesh | Ganglionic blockers | en_US |
dc.title | Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: Involvement of the peripheral autonomic nervous system | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000258628400052 | tr_TR |
dc.identifier.scopus | 2-s2.0-47549099175 | tr_TR |
dc.relation.tubitak | T-2003/50 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0001-9496-1475 | tr_TR |
dc.contributor.orcid | 0000-0003-2918-5064 | tr_TR |
dc.identifier.startpage | 315 | tr_TR |
dc.identifier.endpage | 322 | tr_TR |
dc.identifier.volume | 589 | tr_TR |
dc.identifier.issue | 1-3 | tr_TR |
dc.relation.journal | European Journal of Pharmacology | en_US |
dc.contributor.buuauthor | Cansev, Mehmet | - |
dc.contributor.buuauthor | İlçöl, Yeşim Özarda | - |
dc.contributor.buuauthor | Yılmaz, Mustafa Sertaç | - |
dc.contributor.buuauthor | Hamurtekin, Emre | - |
dc.contributor.buuauthor | Ulus, İsmail Hakki | - |
dc.contributor.researcherid | M-9071-2019 | tr_TR |
dc.contributor.researcherid | AAH-1571-2021 | tr_TR |
dc.contributor.researcherid | D-5340-2015 | tr_TR |
dc.contributor.researcherid | AAL-8873-2021 | tr_TR |
dc.identifier.pubmed | 18561911 | tr_TR |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 | en_US |
dc.contributor.scopusid | 8872816100 | tr_TR |
dc.contributor.scopusid | 35741320500 | tr_TR |
dc.contributor.scopusid | 8895544100 | tr_TR |
dc.contributor.scopusid | 8717648500 | tr_TR |
dc.contributor.scopusid | 7004271086 | tr_TR |
dc.subject.scopus | Citicoline; Neuroprotective Agents; Glycerylphosphorylcholine | en_US |
dc.subject.emtree | Atropine methyl nitrate | en_US |
dc.subject.emtree | Choline | en_US |
dc.subject.emtree | Citicoline | en_US |
dc.subject.emtree | Glucagon | en_US |
dc.subject.emtree | Hemicholinium 3 | en_US |
dc.subject.emtree | Hexamethonium | en_US |
dc.subject.emtree | Mecamylamine | en_US |
dc.subject.emtree | Phosphorylcholine | en_US |
dc.subject.emtree | Adrenalectomy | en_US |
dc.subject.emtree | Alpha adrenergic receptor blocking | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Autonomic nervous system | en_US |
dc.subject.emtree | Cholinergic system | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Dose response | en_US |
dc.subject.emtree | Glucagon blood level | en_US |
dc.subject.emtree | Glucagon release | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Neuroendocrinology | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Rat | en_US |
Koleksiyonlarda Görünür: | PubMed Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.